OptimizeRx publishes corporate presentation on AI-enabled platform for pharma-HCP-patient engagement

OptimizeRx Corporation

OptimizeRx Corporation

OPRX

0.00
  • OptimizeRx outlined fiscal 2026 guidance for revenue of $95 million-$100 million, adjusted EBITDA of $21 million-$25 million.
  • Q1 2026 revenue totaled $19.8 million; adjusted EBITDA was $3.3 million.
  • Shares outstanding stood at about 18,800,000; stock traded at USD 5.38, implying market value of about USD 101 million.
  • Cash and cash equivalents were USD 20.2 million; total debt was USD 23.6 million.
  • Net revenue retention was 110%; revenue per average full-time employee was USD 801,000.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.